NASDAQ:MLYS Mineralys Therapeutics (MLYS) Stock Price, News & Analysis $16.78 +0.61 (+3.77%) Closing price 04:00 PM EasternExtended Trading$16.35 -0.43 (-2.56%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mineralys Therapeutics Stock (NASDAQ:MLYS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mineralys Therapeutics alerts:Sign Up Key Stats Today's Range$16.28▼$17.0850-Day Range$8.76▼$16.8752-Week Range$8.24▼$18.38Volume1.34 million shsAverage Volume332,564 shsMarket Capitalization$1.05 billionP/E RatioN/ADividend YieldN/APrice Target$27.00Consensus RatingBuy Company OverviewMineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Read More… Remove Ads Mineralys Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreMLYS MarketRank™: Mineralys Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 391st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMineralys Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMineralys Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Mineralys Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($4.23) to ($4.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mineralys Therapeutics is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mineralys Therapeutics is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMineralys Therapeutics has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mineralys Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.18% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Mineralys Therapeutics has recently increased by 14.86%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMineralys Therapeutics does not currently pay a dividend.Dividend GrowthMineralys Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.18% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Mineralys Therapeutics has recently increased by 14.86%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.74 News SentimentMineralys Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Mineralys Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for MLYS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows1 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Mineralys Therapeutics insiders have bought 9,597.48% more of their company's stock than they have sold. Specifically, they have bought $25,599,996.00 in company stock and sold $263,986.00 in company stock.Percentage Held by Insiders33.24% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mineralys Therapeutics' insider trading history. Receive MLYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MLYS Stock News HeadlinesSamsara Biocapital Gp, Llc Acquires 600,000 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockMarch 18, 2025 | insidertrades.comMineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in MarchMarch 25 at 1:04 PM | insidermonkey.comElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.March 25, 2025 | True Market Insiders (Ad)Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ETMarch 25 at 8:00 AM | globenewswire.comBuy Rating Justified for Mineralys Therapeutics, Inc. Due to Promising Study Results and Manageable Safety ProfileMarch 20, 2025 | tipranks.comMineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading Volume Following Insider Buying ActivityMarch 20, 2025 | americanbankingnews.comMineralys Therapeutics to Present Phase 2 Trial Data on Lorundrostat for Uncontrolled Hypertension at ACC.25March 19, 2025 | nasdaq.comMineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25March 19, 2025 | msn.comSee More Headlines MLYS Stock Analysis - Frequently Asked Questions How have MLYS shares performed this year? Mineralys Therapeutics' stock was trading at $12.31 on January 1st, 2025. Since then, MLYS shares have increased by 36.3% and is now trading at $16.78. View the best growth stocks for 2025 here. How were Mineralys Therapeutics' earnings last quarter? Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released its quarterly earnings data on Wednesday, February, 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.02. When did Mineralys Therapeutics IPO? Mineralys Therapeutics (MLYS) raised $180 million in an IPO on Friday, February 10th 2023. The company issued 12,000,000 shares at $14.00-$16.00 per share. Who are Mineralys Therapeutics' major shareholders? Top institutional shareholders of Mineralys Therapeutics include Orbimed Advisors LLC (3.24%), Vanguard Group Inc. (2.88%), Adams Street Partners LLC (2.27%) and Millennium Management LLC (2.21%). Insiders that own company stock include Brian Taylor Slingsby, Samsara Biocapital Gp, Llc, Ra Capital Management, LP, Hbm Healthcare Investments (Ca, Jon Congleton, Adam Scott Levy and David Malcom Rodman. View institutional ownership trends. How do I buy shares of Mineralys Therapeutics? Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mineralys Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mineralys Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings2/12/2025Today3/25/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MLYS CIK1933414 Webwww.mineralystx.com Phone888-378-6240FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$27.00 High Stock Price Target$30.00 Low Stock Price Target$24.00 Potential Upside/Downside+60.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-177,810,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.97% Return on Assets-62.40% Debt Debt-to-Equity RatioN/A Current Ratio14.02 Quick Ratio14.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.84 per share Price / Book4.37Miscellaneous Outstanding Shares62,785,000Free Float33,271,000Market Cap$1.05 billion OptionableOptionable Beta1.50 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:MLYS) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.